Bharat Immunological & Biological Corporation Ltd. (BIBCL) is an Indian pharmaceutical company that produces pharmaceutical formulations, such as Oral Polio Vaccine, Hepatitis B vaccine, zinc tablets, and sanitizers. The company was incorporated in 1989 in Uttar Pradesh.
BIBCL went public in 1994 and listed its shares on Delhi, Mumbai, and Kanpur stock exchanges. The Bombay Stock Exchange has allotted the number 524663 to BIBCL. As of March 31, 2022, the company’s total market capitalisation is at Rs. 121.34 crore. Bharat Biotech share price as of the same date was Rs. 28.10. Bharat Biotech stock price hit a 52-week high of Rs. 94.50 and recorded a 52-week low of Rs. 28. The latest price to book ratio of Bharat Immunological shares was at 0.88 as of March 31, 2022.
The pharmaceutical company has a number of worthy milestones. In 1996, BIBCL started bulk production of Oral Polio Vaccines. It received its WHO-GMP certification in 1999. The next year, Bharat Immunological & Biological Corporation Ltd. bagged an order from UNICEF and the Ministry of Health and Family Welfare, Government of India for 170 million doses. In 2001, the company bagged another vaccine order of 270 million doses from UNICEF and the Ministry of Health and Family Welfare.
In 2006, the company made it to the list of top 20 biotech companies in India for its performance. Since 2007, BIBCL has launched a number of other products, including zinc tablets for treating diarrhoea among young children, diarrhoea treatment kits, bivalent oral polio vaccine, and therapeutic food.
For the quarter ended December 31st 2021, Bharat Immunological & Biological Corporation Ltd. posted total revenues of Rs. 17.43 crores. For the same period in the previous year, the company posted revenues of Rs. 25.20 crores. BIBCL recorded a loss of Rs. 0.33 crores for the quarter ended December 31st 2021. For the same period in the previous year, the company recorded a total loss of Rs. 1.90 crores. Bharat Immunological & Biological Corporation Ltd. posted earnings per share of -Rs.0.08 for the quarter ended December 31st 2021 compared to -Rs. 0.44 for the same period in the previous year.
Bharat Immunological & Biological Corporation share price as on 02 Mar 2026 is Rs. 17.21. Over the past 6 months, the Bharat Immunological & Biological Corporation share price has decreased by 22.09% and in the last one year, it has decreased by 30.83%. The 52-week low for Bharat Immunological & Biological Corporation share price was Rs. 16.55 and 52-week high was Rs. 28.8.
Bharat Immunological & Biological Corporation Ltd. (BIBCL) is an Indian pharmaceutical company that produces pharmaceutical formulations, such as Oral Polio Vaccine, Hepatitis B vaccine, zinc tablets, and sanitizers. The company was incorporated in 1989 in Uttar Pradesh.
BIBCL went public in 1994 and listed its shares on Delhi, Mumbai, and Kanpur stock exchanges. The Bombay Stock Exchange has allotted the number 524663 to BIBCL. As of March 31, 2022, the company’s total market capitalisation is at Rs. 121.34 crore. Bharat Biotech share price as of the same date was Rs. 28.10. Bharat Biotech stock price hit a 52-week high of Rs. 94.50 and recorded a 52-week low of Rs. 28. The latest price to book ratio of Bharat Immunological shares was at 0.88 as of March 31, 2022.
The pharmaceutical company has a number of worthy milestones. In 1996, BIBCL started bulk production of Oral Polio Vaccines. It received its WHO-GMP certification in 1999. The next year, Bharat Immunological & Biological Corporation Ltd. bagged an order from UNICEF and the Ministry of Health and Family Welfare, Government of India for 170 million doses. In 2001, the company bagged another vaccine order of 270 million doses from UNICEF and the Ministry of Health and Family Welfare.
In 2006, the company made it to the list of top 20 biotech companies in India for its performance. Since 2007, BIBCL has launched a number of other products, including zinc tablets for treating diarrhoea among young children, diarrhoea treatment kits, bivalent oral polio vaccine, and therapeutic food.
For the quarter ended December 31st 2021, Bharat Immunological & Biological Corporation Ltd. posted total revenues of Rs. 17.43 crores. For the same period in the previous year, the company posted revenues of Rs. 25.20 crores. BIBCL recorded a loss of Rs. 0.33 crores for the quarter ended December 31st 2021. For the same period in the previous year, the company recorded a total loss of Rs. 1.90 crores. Bharat Immunological & Biological Corporation Ltd. posted earnings per share of -Rs.0.08 for the quarter ended December 31st 2021 compared to -Rs. 0.44 for the same period in the previous year.
Bharat Immunological & Biological Corporation share price as on 02 Mar 2026 is Rs. 17.21. Over the past 6 months, the Bharat Immunological & Biological Corporation share price has decreased by 22.09% and in the last one year, it has decreased by 30.83%. The 52-week low for Bharat Immunological & Biological Corporation share price was Rs. 16.55 and 52-week high was Rs. 28.8.
